Compile Data Set for Download or QSAR
maximum 50k data
Found 666 with Last Name = 'miyazaki' and Initial = 't'
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148155(US8962612, 26)
Affinity DataKi:  0.680nM ΔG°:  -54.4kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148163(US8962612, 66)
Affinity DataKi:  0.75nM ΔG°:  -54.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148169(US8962612, 80)
Affinity DataKi:  0.850nM ΔG°:  -53.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148165(US8962612, 74)
Affinity DataKi:  0.880nM ΔG°:  -53.8kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148171(US8962612, 86)
Affinity DataKi:  0.950nM ΔG°:  -53.6kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148154(US8962612, 23)
Affinity DataKi:  1.10nM ΔG°:  -53.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148156(US8962612, 28)
Affinity DataKi:  1.10nM ΔG°:  -53.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135790(US8853242, 162)
Affinity DataKi:  1.20nM ΔG°:  -50.9kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135785(US8853242, 152)
Affinity DataKi:  1.30nM ΔG°:  -50.7kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135780(US8853242, 60)
Affinity DataKi:  1.30nM ΔG°:  -50.7kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148167(US8962612, 78)
Affinity DataKi:  1.30nM ΔG°:  -52.8kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135783(US8853242, 148)
Affinity DataKi:  1.40nM ΔG°:  -50.5kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135782(US8853242, 147)
Affinity DataKi:  1.60nM ΔG°:  -50.2kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148164(US8962612, 69)
Affinity DataKi:  1.60nM ΔG°:  -52.2kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135795(US8853242, 192)
Affinity DataKi:  1.80nM ΔG°:  -49.9kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135792(US8853242, 170)
Affinity DataKi:  1.90nM ΔG°:  -49.8kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148162(US8962612, 62)
Affinity DataKi:  1.90nM ΔG°:  -51.8kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135796(US8853242, 211)
Affinity DataKi:  2.30nM ΔG°:  -49.3kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148161(US8962612, 61)
Affinity DataKi:  2.5nM ΔG°:  -51.1kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148157(US8962612, 44)
Affinity DataKi:  2.70nM ΔG°:  -50.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148166(US8962612, 76)
Affinity DataKi:  2.70nM ΔG°:  -50.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135788(US8853242, 160)
Affinity DataKi:  3.30nM ΔG°:  -48.4kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135789(US8853242, 161)
Affinity DataKi:  3.40nM ΔG°:  -48.3kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148153(US8962612, 8)
Affinity DataKi:  3.60nM ΔG°:  -50.1kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135781(US8853242, 114)
Affinity DataKi:  3.70nM ΔG°:  -48.1kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148168(US8962612, 79)
Affinity DataKi:  3.70nM ΔG°:  -50.1kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148160(US8962612, 60)
Affinity DataKi:  3.90nM ΔG°:  -49.9kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135784(US8853242, 151)
Affinity DataKi:  4.10nM ΔG°:  -47.9kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148170(US8962612, 81)
Affinity DataKi:  4.20nM ΔG°:  -49.7kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetFree fatty acid receptor 1(Rattus norvegicus)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50386646(CHEMBL2048622)
Affinity DataKi:  4.20nMAssay Description:Displacement of 3-[4-({2',6'-dimethyl-6-[(4-[3H])phenylmethoxy]biphenyl-3-yl}methoxy)phenyl] propanoic acid from rat GPR40 receptor expressed in CHO ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148152(US8962612, 4)
Affinity DataKi:  4.30nM ΔG°:  -49.7kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetFree fatty acid receptor 1(Rattus norvegicus)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50386648(CHEMBL2048625)
Affinity DataKi:  4.5nMAssay Description:Displacement of 3-[4-({2',6'-dimethyl-6-[(4-[3H])phenylmethoxy]biphenyl-3-yl}methoxy)phenyl] propanoic acid from rat GPR40 receptor expressed in CHO ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetFree fatty acid receptor 1(Rattus norvegicus)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50386650(CHEMBL2048627)
Affinity DataKi:  4.5nMAssay Description:Displacement of 3-[4-({2',6'-dimethyl-6-[(4-[3H])phenylmethoxy]biphenyl-3-yl}methoxy)phenyl] propanoic acid from rat GPR40 receptor expressed in CHO ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetFree fatty acid receptor 1(Rattus norvegicus)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50386644(CHEMBL2048618)
Affinity DataKi:  4.5nMAssay Description:Displacement of 3-[4-({2',6'-dimethyl-6-[(4-[3H])phenylmethoxy]biphenyl-3-yl}methoxy)phenyl] propanoic acid from rat GPR40 receptor expressed in CHO ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135794(US8853242, 187)
Affinity DataKi:  4.60nM ΔG°:  -47.6kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135791(US8853242, 164)
Affinity DataKi:  4.70nM ΔG°:  -47.5kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetFree fatty acid receptor 1(Rattus norvegicus)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50386649(CHEMBL2048626)
Affinity DataKi:  5.10nMAssay Description:Displacement of 3-[4-({2',6'-dimethyl-6-[(4-[3H])phenylmethoxy]biphenyl-3-yl}methoxy)phenyl] propanoic acid from rat GPR40 receptor expressed in CHO ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135786(US8853242, 157)
Affinity DataKi:  5.30nM ΔG°:  -47.2kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetFree fatty acid receptor 1(Rattus norvegicus)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50386641(CHEMBL2048615)
Affinity DataKi:  5.60nMAssay Description:Displacement of 3-[4-({2',6'-dimethyl-6-[(4-[3H])phenylmethoxy]biphenyl-3-yl}methoxy)phenyl] propanoic acid from rat GPR40 receptor expressed in CHO ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135793(US8853242, 171)
Affinity DataKi:  6.20nM ΔG°:  -46.8kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetFree fatty acid receptor 1(Rattus norvegicus)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50386651(CHEMBL2048628)
Affinity DataKi:  6.20nMAssay Description:Displacement of 3-[4-({2',6'-dimethyl-6-[(4-[3H])phenylmethoxy]biphenyl-3-yl}methoxy)phenyl] propanoic acid from rat GPR40 receptor expressed in CHO ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetFree fatty acid receptor 1(Rattus norvegicus)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50386640(CHEMBL2048614)
Affinity DataKi:  6.20nMAssay Description:Displacement of 3-[4-({2',6'-dimethyl-6-[(4-[3H])phenylmethoxy]biphenyl-3-yl}methoxy)phenyl] propanoic acid from rat GPR40 receptor expressed in CHO ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetFree fatty acid receptor 1(Rattus norvegicus)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50386637(CHEMBL2048623)
Affinity DataKi:  6.40nMAssay Description:Displacement of 3-[4-({2',6'-dimethyl-6-[(4-[3H])phenylmethoxy]biphenyl-3-yl}methoxy)phenyl] propanoic acid from rat GPR40 receptor expressed in CHO ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148159(US8962612, 49)
Affinity DataKi:  6.60nM ΔG°:  -48.6kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetFree fatty acid receptor 1(Rattus norvegicus)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50386639(CHEMBL2048619)
Affinity DataKi:  6.70nMAssay Description:Displacement of 3-[4-({2',6'-dimethyl-6-[(4-[3H])phenylmethoxy]biphenyl-3-yl}methoxy)phenyl] propanoic acid from rat GPR40 receptor expressed in CHO ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetFree fatty acid receptor 1(Rattus norvegicus)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50386638(CHEMBL2048620)
Affinity DataKi:  6.70nMAssay Description:Displacement of 3-[4-({2',6'-dimethyl-6-[(4-[3H])phenylmethoxy]biphenyl-3-yl}methoxy)phenyl] propanoic acid from rat GPR40 receptor expressed in CHO ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetFree fatty acid receptor 1(Rattus norvegicus)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50386642(CHEMBL2048616)
Affinity DataKi:  6.70nMAssay Description:Displacement of 3-[4-({2',6'-dimethyl-6-[(4-[3H])phenylmethoxy]biphenyl-3-yl}methoxy)phenyl] propanoic acid from rat GPR40 receptor expressed in CHO ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM148158(US8962612, 46)
Affinity DataKi:  6.90nM ΔG°:  -48.5kJ/molepH: 7.4 T: 2°CAssay Description:A test compound and 150 uM of a DMSO solution of 5-carboxamide tryptamine (5-CT) were added to a 96-well plate at 2 ul/well and suspended in the incu...More data for this Ligand-Target Pair
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 5A(Homo sapiens (Human))
Astellas Pharma

US Patent
LigandPNGBDBM135787(US8853242, 159)
Affinity DataKi:  7.10nM ΔG°:  -46.5kJ/molepH: 7.5 T: 2°CAssay Description:A solution of the compound to be tested and 100 μM 5-CT (5-carboxamidetriptamine) in DMSO was added to a 96-well plate at 2 μl/well, suspen...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetFree fatty acid receptor 1(Rattus norvegicus)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50386647(CHEMBL2048624)
Affinity DataKi:  8.20nMAssay Description:Displacement of 3-[4-({2',6'-dimethyl-6-[(4-[3H])phenylmethoxy]biphenyl-3-yl}methoxy)phenyl] propanoic acid from rat GPR40 receptor expressed in CHO ...More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 666 total ) | Next | Last >>
Jump to: